News | March 18, 2024
AstraZeneca to acquire Amolyt Pharma
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Varenicline is indicated for smoking cessation in adults
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Subscribe To Our Newsletter & Stay Updated
